<DOC>
	<DOCNO>NCT01827267</DOCNO>
	<brief_summary>This Phase 2 , therapeutic-exploratory , adaptive design , open-label , multicenter , multinational study evaluate neratinib monotherapy neratinib plus temsirolimus combination therapy patient non-small cell lung cancer ( NSCLC ) document somatic HER2 mutation .</brief_summary>
	<brief_title>Neratinib With Without Temsirolimus Patients With HER2 Activating Mutations Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>This Phase 2 , therapeutic-exploratory , adaptive design , open-label , multicenter , multinational study evaluate neratinib monotherapy neratinib plus temsirolimus combination therapy patient NSCLC document somatic HER2 mutation . Patients randomize study entry 1 2 treatment arm : - Arm A : neratinib 240 mg orally daily , - Arm B : neratinib 240 mg orally daily plus temsirolimus 8 mg weekly intravenous ( IV ) infusion . In case disease progression , patient initially assign neratinib monotherapy arm give option add temsirolimus 8 mg IV weekly . All patient combination therapy may dose-escalated respect temsirolimus dose 15 mg/week end first cycle treatment combination , well tolerated physician 's discretion . In event neratinib 240 mg/day plus temsirolimus 15 mg/week dose well tolerate , patient subsequently dose reduce back neratinib 240 mg/day plus temsirolimus 8 mg/week . Dosing continuous nominal 3-week cycle evidence progressive disease , unacceptable toxicity , patient withdrawal consent . All eligible patient enrol disease measure radiographically baseline . Patients undergo radiographic evaluation disease every 6 week disease progression withdrawal study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Aged ≥18 year time signing informed consent . Histologically confirm diagnosis NSCLC , advance ( stage IIIB ) metastatic ( stage IV ) . Documented somatic ErbB2 ( HER2 ) activate mutation . Previous treatment investigational agent ≤30 day prior initiation investigational product . Prior exposure neratinib mTOR inhibitor Note : There additional inclusion exclusion criterion . The study center determine meet criterion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Lung cancer</keyword>
	<keyword>Puma</keyword>
	<keyword>neratinib</keyword>
</DOC>